Clinical Trial Update: Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies [Phase 2]

View source ↗

Summary

Phase II study assessing AT-101 as a single-agent therapy in relapsed or refractory B-cell malignancies has completed, reporting safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• AT-101 (gossypol acetic acid)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Follicular Lymphoma, Diffuse Large Cell Lymphoma | Phase 2 | Status: COMPLETED